Page last updated: 2024-12-11
cgs 35066
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
CGS 35066: an endothelin-converting enzyme-1 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9863167 |
| CHEMBL ID | 146936 |
| SCHEMBL ID | 7697566 |
| MeSH ID | M0358514 |
Synonyms (16)
| Synonym |
|---|
| cgs 35066 |
| cgs-35066 |
| (s)-3-(dibenzo[b,d]furan-3-yl)-2-(phosphonomethylamino)propanoic acid |
| 3-dibenzofuran-3-yl-2-(phosphonomethyl-amino)-propionic acid |
| bdbm50084893 |
| CHEMBL146936 , |
| (2s)-3-dibenzofuran-3-yl-2-(phosphonomethylamino)propanoic acid |
| SCHEMBL7697566 |
| ?-[(s)-(phosphonomethyl)amino]-3-dibenzofuranpropanoic acid |
| 261619-50-5 |
| AKOS024457142 |
| J-016288 |
| 3-dibenzofuranpropanoic acid, alpha-((phosphonomethyl)amino)-, (alphas)- |
| (s)-3-dibenzofuran-3-yl-2-[phosphonomethylamino]-propionic acid |
| (s)-3-(dibenzo[b,d]furan-3-yl)-2-((phosphonomethyl)amino)propanoic acid |
| alpha-[(s)-(phosphonomethyl)amino]-3-dibenzofuranpropanoic acid |
Research Excerpts
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with CGS 35066 significantly attenuated basilar arterial narrowing at a dose of 1 mg/kg in both protocols." | ( Attenuation of SAH-induced cerebral vasospasm by a selective ECE inhibitor. Chang, CZ; Howng, SL; Jeng, AY; Kwan, AL; Lin, CL; Wu, SC, 2002) | 0.65 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "8-fold rightward shift of dose-response curve; P<0." | ( Role of endothelin-converting enzyme, chymase and neutral endopeptidase in the processing of big ET-1, ET-1(1-21) and ET-1(1-31) in the trachea of allergic mice. De Campo, BA; Goldie, RG; Henry, PJ; Jeng, AY, 2002) | 0.31 |
| " The dose-response curve for ET-1 was shifted to the left in the diabetics, so that at some lower doses of ET-1 the vasoconstriction was greater than in the controls." | ( Diabetes-associated changes and role of N epsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction. Kamata, K; Kobayashi, T; Matsumoto, T; Ozawa, Y; Taguchi, K, 2010) | 0.36 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (5)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Neprilysin | Rattus norvegicus (Norway rat) | IC50 (µMol) | 2.3000 | 0.0010 | 0.1702 | 2.3000 | AID143636 |
| Neprilysin | Oryctolagus cuniculus (rabbit) | IC50 (µMol) | 2.3000 | 0.0004 | 0.6611 | 8.2000 | AID147216 |
| Neprilysin | Homo sapiens (human) | IC50 (µMol) | 2.3000 | 0.0002 | 0.5422 | 6.7000 | AID444547 |
| Angiotensin-converting enzyme | Homo sapiens (human) | IC50 (µMol) | 1.1610 | 0.0001 | 0.5336 | 10.0000 | AID444547; AID444548 |
| Endothelin-converting enzyme 1 | Homo sapiens (human) | IC50 (µMol) | 0.0220 | 0.0120 | 0.5678 | 2.0000 | AID228593; AID444548; AID67196 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (87)
Molecular Functions (23)
Ceullar Components (32)
Bioassays (8)
Research
Studies (18)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (77.78) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.70
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.70) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (5.56%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (94.44%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||